JACC:连续高NSE值对OHCA不良结局有较强的预测性

2015-05-22 张旭栋译 MedSci原创

卢森堡中心医院Pascal Stammet博士等人探索了神经元特异性烯醇化酶对于院外心脏骤停不良结局的预测性,并同时探索了温度管理对其的影响,研究成果发表在5月份的Circulation期刊上。背景: 神经元特异性烯醇化酶(NSE)是心脏骤停后神经系统预后的一种广泛使用的生物标志物,但是,由于缺乏标准化的方法和不确定的温度管理影响,推荐的临界值相关性一直备受质疑。目的: 本研究旨在

卢森堡中心医院Pascal Stammet博士等人探索了神经元特异性烯醇化酶对于院外心脏骤停不良结局的预测性,并同时探索了温度管理对其的影响,研究成果发表在5月份的Circulation期刊上。
背景:

神经元特异性烯醇化酶(NSE)是心脏骤停后神经系统预后的一种广泛使用的生物标志物,但是,由于缺乏标准化的方法和不确定的温度管理影响,推荐的临界值相关性一直备受质疑。
目的:
 
本研究旨在探索院外心脏骤停(OHCA)患者中NSE对于预后起到的预测作用。

研究纳入了686例OHCA住院患者,将其随机分配为33℃或36℃温度管理组。自主循环恢复分别为24,48,72小时后评估血液样品中NSE的水平值。主要结局是6个月后,通过神经功能CPC评分(cerebral performance category score)从而评价神经系统结局。

结果:NSE对于神经系统结局有着显著的预测性,目标温度不会显著影响NSE值。24,48,72小时候,有利结局与不利结局中位NSE比值分别为18ng/ml比35ng/ml,15ng/ml比61ng/ml,以及12ng/ml比54ng/ml(P<0.001)。48和72小时,NSE通过ROC曲线下的面积从而对于神经系统结局的预测值分别为0.85和0.86。高NSE值的假阳性率≤5%,95%置信区间能够可靠地预测结果。
结局:
 
连续高NSE值对OHCA不良结局有较强的预测性。33℃或36℃温度管理对于NSE水平并没有显著的影响。


原始出处:

Stammet P, Collignon O, Hassager C, et al. Neuron-Specific Enolase as a Predictor of Death or Poor Neurological Outcome After Out-of-Hospital Cardiac Arrest and Targeted Temperature Management at 33 degrees C and 36 degrees C. Journal of the American College of Cardiology. 2015;65(19):2104-14.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1685460, encodeId=734c1685460f2, content=<a href='/topic/show?id=2139854472' target=_blank style='color:#2F92EE;'>#HCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8544, encryptionId=2139854472, topicName=HCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4a28195983, createdName=tsing_hit, createdTime=Mon Jun 01 00:11:00 CST 2015, time=2015-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853339, encodeId=de6218533392c, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Aug 24 14:11:00 CST 2015, time=2015-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24865, encodeId=7bb624865ca, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Mon May 25 19:08:00 CST 2015, time=2015-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325029, encodeId=a800132502911, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun May 24 07:11:00 CST 2015, time=2015-05-24, status=1, ipAttribution=)]
    2015-06-01 tsing_hit
  2. [GetPortalCommentsPageByObjectIdResponse(id=1685460, encodeId=734c1685460f2, content=<a href='/topic/show?id=2139854472' target=_blank style='color:#2F92EE;'>#HCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8544, encryptionId=2139854472, topicName=HCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4a28195983, createdName=tsing_hit, createdTime=Mon Jun 01 00:11:00 CST 2015, time=2015-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853339, encodeId=de6218533392c, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Aug 24 14:11:00 CST 2015, time=2015-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24865, encodeId=7bb624865ca, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Mon May 25 19:08:00 CST 2015, time=2015-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325029, encodeId=a800132502911, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun May 24 07:11:00 CST 2015, time=2015-05-24, status=1, ipAttribution=)]
    2015-08-24 hbwxf
  3. [GetPortalCommentsPageByObjectIdResponse(id=1685460, encodeId=734c1685460f2, content=<a href='/topic/show?id=2139854472' target=_blank style='color:#2F92EE;'>#HCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8544, encryptionId=2139854472, topicName=HCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4a28195983, createdName=tsing_hit, createdTime=Mon Jun 01 00:11:00 CST 2015, time=2015-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853339, encodeId=de6218533392c, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Aug 24 14:11:00 CST 2015, time=2015-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24865, encodeId=7bb624865ca, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Mon May 25 19:08:00 CST 2015, time=2015-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325029, encodeId=a800132502911, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun May 24 07:11:00 CST 2015, time=2015-05-24, status=1, ipAttribution=)]
    2015-05-25 huaxipanxing

    看看

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1685460, encodeId=734c1685460f2, content=<a href='/topic/show?id=2139854472' target=_blank style='color:#2F92EE;'>#HCA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8544, encryptionId=2139854472, topicName=HCA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ad4a28195983, createdName=tsing_hit, createdTime=Mon Jun 01 00:11:00 CST 2015, time=2015-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1853339, encodeId=de6218533392c, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Mon Aug 24 14:11:00 CST 2015, time=2015-08-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=24865, encodeId=7bb624865ca, content=看看, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ee0d1618732, createdName=huaxipanxing, createdTime=Mon May 25 19:08:00 CST 2015, time=2015-05-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1325029, encodeId=a800132502911, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sun May 24 07:11:00 CST 2015, time=2015-05-24, status=1, ipAttribution=)]

相关资讯

非酒精性脂肪肝生物标志物已经被识别

在欧盟国家中有40%的个体都遭受着非酒精性脂肪性肝炎的痛苦,在当前富裕社会下这种疾病的流行率越来越高,其也是个体糖尿病和体重过度增加的直接结果,当前研究者并不可能预测这种疾病的未来发展情况,而其直接的结果似乎只能是肝硬化和肝癌,此外其也会增加个体患心脏病发作及肾脏损伤的风险,未来研究者或将利用不同生物标志物的风险评分来对该疾病进行预测。 来自维也纳医科大学的研究者表示,我们开发的这种风险

Breast Cancer Res Treat:VEGF-A水平可作为贝伐单抗治疗乳腺癌的生物标志物

背景:贝伐单抗可改善乳腺癌患者的治疗结果,但已建立生物标志物的缺乏妨碍病人的选择和研究人员证明乳腺癌生存的影响。假定目标,周期性的VEGF-A,成为主要的候选物,我们试图确定VEGF-A水平和系统性回顾的临床结果之间的关系。方法:我们搜索电子数据库和会议论文比较添加贝伐单抗到标准化疗用于乳腺癌治疗的随机对照试验(RCTs)。随机对照试验包括根据VEGF-A血浆水平临床结果的呈现。随机效果模型用来计

J Periodontol:芳香酶抑制剂可增加乳腺癌患者患牙周炎的风险

J Periodontol:芳香酶抑制剂可增加乳腺癌患者患牙周炎的风险 近日有研究表明辅助性使用AI治疗可增加患者患牙周炎的危险,该研究与2015年2月12日在线发表于 JOURNAL OF PERIODONTOLOGY《牙周病学杂志》。芳香酶抑制剂(AI)的应用可导致雌激素水平降低,进而影响骨质密度(BMD)。牙周炎,牙槽骨丧失以及牙齿的丧失均与BMD过低有关。本研究的目的是评估接受A

Nat Rev Cardiol:心衰治疗十年进展总结

Nat Rev Cardiol杂志近日发表了一篇综述。该综述概述了过去 10年心衰治疗的进展,包括药物治疗和器械治疗,强调了急性心衰和射血分数保留心衰治疗遇到的困境,并对未来心衰治疗进行展望。全文编译如下: 一、CRT 治疗显著改善射血分数减少心衰患者预后 过去 20年里,心血管治疗领域最为巨大的进展之一是心脏再同步化治疗(CRT)应用于射血分数减少心力衰竭(HFREF)患者的

JACC:分泌神经素:一种新的心肌细胞钙调控相关预后生物标记物

生物标志物是个体患者特殊的生理病理学指针。目前心血管生物标志物临床常用的有B型钠尿肽(反映心肌应激),心肌特异性肌钙蛋白(衡量心肌受损)。然而,像心肌钙平衡之类的生物标志物不能评估心血管疾病。越来越多的证据提示:嗜铬粒蛋白-分泌粒蛋白(蛋白质粒家族)在心脏病理生理学上起着重要作用,能够作为心血管生物标志物。其中一员备受关注的成员是高容量,低亲和力的钙结合蛋白分泌粒蛋白II。分泌粒蛋白II被蛋白

Oncogene:特殊生物标志物可向恶性前列腺癌发送信号促其侵袭

近日,来自密歇根大学的研究者在杂志Oncogene上刊登了他们的最新研究成果,研究者发现了一种新型的生物标志物,其或许对于诊断和治疗前列腺癌非常重要。机体中的生物标志物就类似于汽车的警报灯,当其发送信号的时候或许就需要进行修理,在我们机体中,生物标志物就可以提示我们机体发生了某些故障,或者是我们即将生病的征兆。 Renny Franceschi教授指出,我们非常感兴趣去寻找可以区分恶性疾病的